Contrasting with prior findings: a population-based cohort study of fibrate exposure and open-angle glaucoma risk in patients with hyperlipidemia

Read full text Summarise with VIRAT
Authors: Guan‐Ling Lin, Shih-Chia Lin, Joseph Jordan Keller, Evelyn Jou-Chen Huang, Li‐Hsuan Wang
Cited by: 0
References: 69

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This study investigated the association between fibrate use and the risk of open-angle glaucoma (OAG) in patients with hyperlipidemia. A nationwide retrospective cohort study was conducted using Taiwan’s Longitudinal Generation Tracking Database (LGTD 2000). Patients aged ≥ 50 years newly diagnosed with hyperlipidemia between 2001 and 2013 were included. New fibrate users were stratified by adherence, with higher proportion of days covered (PDC) users (≥ 50%) as the exposure group, while lower PDC users (20–50%) and nonusers served as comparators. Propensity score matching (1:1) created balanced cohorts, followed for up to five years. OAG risk was estimated using marginal Cox models. In matched cohorts, OAG incidence was 4.98 per 1000 person-years in higher PDC users and 3.29 in lower PDC users. Compared with nonusers, higher PDC users had 4.78 versus 2.83 per 1000 person-years. Higher PDC was not significantly associated with OAG risk versus lower PDC (adjusted hazard ratio [aHR] 1.48; 95% confidence interval [CI] 0.95–2.29), but risk was elevated compared with nonuse (aHR 1.68; 95% CI 1.09–2.61). Patients with ≥ 303 cumulative defined daily doses/year and those treated ≥ 2 years had increased risks, with aHRs of 3.75 (95% CI 2.21–6.38) and 1.70 (95% CI 1.04–2.76), both showing linear trends. Higher cumulative doses and longer duration of fibrate therapy were associated with increased OAG incidence. These findings require further evaluation, including clinical and cost-effectiveness considerations, before routine ophthalmologic surveillance is considered.

Fields of Study & Subjects

Glaucoma and retinal disorders Drug-Induced Ocular Toxicity Lipoproteins and Cardiovascular Health

Publication details

Journal / source
European journal of medical research
Volume
31
Issue
1
Publication date
22 March 2026
Language
EN